Falsified Ibrance in Trinidad and Tobago: when a registered drug is faked

Two alerts on one day

On 3 February 2026 the Ministry of Health of Trinidad and Tobago, through its Chemistry, Food and Drugs Division (CFDD), issued an alert on falsified Wegovy tablets, a weight-loss product that the Ministry said "is not authorised for use in Trinidad and Tobago"³. The same day TTT News reported a second CFDD alert, this time on falsified Ibrance (palbociclib) capsules, a drug used for certain breast cancers in adults¹. The two cases look alike but are opposite problems. Wegovy tablets have no legal route into the country, so any pack found locally is suspect. Ibrance, the Ministry said, "is registered for use in Trinidad and Tobago"¹. A falsified copy of a registered drug can sit beside the genuine one in the legal supply chain.

The Ministry said it was acting "out of an abundance of caution" and reported no local cases¹. Patients holding the affected product were told to stop using it immediately and return it to the place of purchase where possible¹.

What WHO found

The CFDD alert was based on WHO Medical Product Alert N°7/2025, dated 15 December 2025¹². WHO said the falsified products were reported in November 2025 and detected in Côte d'Ivoire, Egypt, Lebanon, Libya and Türkiye². Samples tested by the genuine manufacturer "were found to contain no active pharmaceutical ingredient"². WHO listed four lot numbers that are not valid for genuine Ibrance (FS5173, GS4328, LV1850 and TS2190) and five more that are suspicious when combined with other signs (GK2981, GR6491, GT5817, HJ8710 and HJ8715)².

The warning signs are subtle: a label reading "Manufactured by: Pfizer, PO Box 29387, Mission, KS 66201", a security foil showing the logo in black ink, capsules printed "PBC 125" in black ink or with no marking, or capsules in unusual colours such as bright orange¹². WHO also warned that some products "carry genuine lot numbers but display packaging, serialization, and capsule printing anomalies"². The consequence, in WHO's words, is "treatment failure, uncontrolled cancer progression, and a higher risk of death"².

Why a missing ingredient is so dangerous in oncology

Palbociclib is a CDK4/6 inhibitor given with endocrine therapy. In PALOMA-2, 666 postmenopausal women with previously untreated ER-positive, HER2-negative advanced breast cancer had a median progression-free survival of 24.8 months with palbociclib plus letrozole versus 14.5 months with letrozole alone (hazard ratio 0.58)⁴. A falsified capsule with no active ingredient gives no toxicity signal either: the grade 3 or 4 neutropenia seen in 66.4 % of palbociclib patients in the trial would simply not appear⁴. To the patient and the oncologist, the drug could look well tolerated while the disease progresses²⁴.

Quality failures in cancer medicines are not rare. A 2025 study in The Lancet Global Health collected 251 chemotherapy samples from 12 hospitals and 25 pharmacies in Ethiopia, Kenya, Malawi and Cameroon; active ingredient content ranged from 28 % to 120 % of the stated amount, and failure rates were 14 % to 24 % across countries⁵. In Addis Ababa, all 20 cisplatin samples tested in a 2020 study were substandard, with on average 54 % of the stated content⁶. The World Health Organization estimates that "At least 1 in 10 medicines in low- and middle-income countries are substandard or falsified"⁷.

The local context: breast cancer drugs already in short supply

The alert reached a system under strain. In August 2026 the chairman of the North Central Regional Health Authority, Dr Tim Gopeesingh, said the authority was addressing shortages of "the breast cancer drugs exemestane, anastrozole and letrozole", and the Guardian reported that regional health authorities can make emergency purchases whenever NIPDEC supplies are unavailable⁸. When the usual supplier cannot deliver and drugs are bought from other sources, the checks on each new batch matter more; WHO calls for "robust legal frameworks" against substandard and falsified products⁷.

What the law and the regulator provide

Under the Food and Drugs Act (Chap. 30:01), selling an adulterated drug is an offence (section 9), and so is labelling, packaging or selling a drug in a manner "that is false, misleading, or deceptive" as to its character, composition or safety (section 10); penalties under section 33 reach TT$15,000 and three years in prison on indictment⁹. Physicians and patients can check registration status in the Ministry's Regulated Medicines and Substances Portal¹⁰ and report suspected products on the CFDD's Substandard/Falsified & Adverse Drug Reaction Form¹². WHO asks health professionals to report "any unexpected adverse reactions, lack of therapeutic effects or quality defects"².

What it means for practice

For oncologists and pharmacists, the practical checks are on the pack: lot number against the WHO list, the label address, the foil and the capsule print². WHO also asks health professionals to report any lack of therapeutic effect to the national regulator². Systems-level reviews add that authentication technologies can detect fakes in the supply chain but need a strong information system behind them¹³.